 Vertex is growing the reach of its cystic fibrosis drugs Alyftrek and Trikafta with FDA label expansions covering patients with any responsive variant in the cystic fibrosis transmembrane conductance regulator (CFTR) gene. 
Content mobilized by FeedBlitz RSS Services, the premium FeedBurner alternative. | 
